{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:33:22Z","timestamp":1793172802566,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-03054-0","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:44:37Z","timestamp":1770252277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of stem cell therapy in patients with Diabetes Mellitus \u2013 a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Manikandan","family":"S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-3432","authenticated-orcid":false,"given":"Roopa","family":"Hariprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavani Shankara","family":"Bagepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"8","key":"3054_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2213-8587(17)30174-2","volume":"5","author":"RM Anjana","year":"2017","unstructured":"Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3054_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/jdi.13404","volume":"12","author":"H Ranjbaran","year":"2021","unstructured":"Ranjbaran H, Mohammadi Jobani B, Amirfakhrian E, Alizadeh-Navaei R. Efficacy of mesenchymal stem cell therapy on glucose levels in type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Investig. 2021;12(5):803\u201310.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"3054_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13643-022-01950-3","volume":"11","author":"S Madani","year":"2022","unstructured":"Madani S, Amanzadi M, Aghayan HR, Setudeh A, Rezaei N, Rouhifard M, et al. Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis. Syst Rev. 2022;11(1):82.","journal-title":"Syst Rev"},{"issue":"3","key":"3054_CR4","doi-asserted-by":"publisher","first-page":"e0247662","DOI":"10.1371\/journal.pone.0247662","volume":"16","author":"J He","year":"2021","unstructured":"He J, Kong D, Yang Z, Guo R, Amponsah AE, Feng B, et al. Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: systematic review and meta-analysis of RCT data. PLoS ONE. 2021;16(3):e0247662.","journal-title":"PLoS ONE"},{"key":"3054_CR5","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions (current version) | Cochrane. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current. Cited 2025 Jun 27."},{"key":"3054_CR6","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3054_CR7","unstructured":"Rayyan | Screening. Available from: https:\/\/new.rayyan.ai\/reviews\/1165815\/screening. Cited 2024 Nov 28."},{"key":"3054_CR8","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. 2019;Available from: https:\/\/www.bmj.com\/content\/366\/bmj.l4898. Cited 2025 Jul 4.","DOI":"10.1136\/bmj.l4898"},{"key":"3054_CR9","unstructured":"GRADE-Handbook.pdf. Available from: https:\/\/evidence-impact.org\/storage\/85\/GRADE-Handbook.pdf. Cited 2025 Jul 4."},{"issue":"8","key":"3054_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00125-023-05934-3","volume":"66","author":"PO Carlsson","year":"2023","unstructured":"Carlsson PO, Espes D, Sisay S, Davies LC, Smith CIE, Svahn MG. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a phase I\/II randomised double-blind placebo-controlled trial. Diabetologia. 2023;66(8):1431\u201341.","journal-title":"Diabetologia"},{"issue":"2","key":"3054_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2337\/db14-0656","volume":"64","author":"PO Carlsson","year":"2015","unstructured":"Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved \u03b2-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015;64(2):587\u201392.","journal-title":"Diabetes"},{"issue":"1","key":"3054_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13287-022-02941-w","volume":"13","author":"M Izadi","year":"2022","unstructured":"Izadi M, Sadr Hashemi Nejad A, Moazenchi M, Masoumi S, Rabbani A, Kompani F, et al. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I\/II randomized placebo-controlled clinical trial. Stem Cell Res Ther. 2022;13(1):264.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"3054_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jcyt.2021.09.015","volume":"24","author":"Z Wu","year":"2022","unstructured":"Wu Z, Xu X, Cai J, Chen J, Huang L, Wu W, et al. Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up. Cytotherapy. 2022;24(4):421\u20137.","journal-title":"Cytotherapy"},{"issue":"7","key":"3054_CR14","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.bbmt.2013.04.011","volume":"19","author":"MJ Haller","year":"2013","unstructured":"Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, et al. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with type 1 diabetes. Biol Blood Marrow Transplant. 2013;19(7):1126\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"3054_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1507\/endocrj.EJ12-0343","volume":"60","author":"J Hu","year":"2013","unstructured":"Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, et al. Long term effects of the implantation of Wharton\u2019s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013;60(3):347\u201357.","journal-title":"Endocr J"},{"key":"3054_CR16","doi-asserted-by":"crossref","unstructured":"Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016;39(1):149\u201357.","DOI":"10.2337\/dc15-0171"},{"issue":"10","key":"3054_CR17","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","volume":"34","author":"N Perico","year":"2023","unstructured":"Perico N, Remuzzi G, Griffin MD, Cockwell P, Maxwell AP, Casiraghi F, et al. Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM). J Am Soc Nephrol. 2023;34(10):1733\u201351.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3054_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13287-022-02848-6","volume":"13","author":"L Zang","year":"2022","unstructured":"Zang L, Li Y, Hao H, Liu J, Cheng Y, Li B, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Res Ther. 2022;13(1):180.","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"3054_CR19","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1177\/0963689719883813","volume":"28","author":"EJ Estrada","year":"2019","unstructured":"Estrada EJ, Decima JL, Bortman G, Roberti J, Romero EB, Samaja G, et al. Combination treatment of autologous bone marrow stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: a randomized controlled trial. Cell Transplant. 2019;28(12):1632\u201340.","journal-title":"Cell Transplant"},{"issue":"7","key":"3054_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4239\/wjd.v8.i7.381","volume":"8","author":"V Sood","year":"2017","unstructured":"Sood V, Bhansali A, Mittal BR, Singh B, Marwaha N, Jain A, et al. Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods. World J Diabetes. 2017;8(7):381.","journal-title":"World J Diabetes"},{"key":"3054_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","volume":"12","author":"DK Packham","year":"2016","unstructured":"Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. EBioMedicine. 2016;12:263\u20139.","journal-title":"EBioMedicine"},{"issue":"3","key":"3054_CR22","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3892\/etm.2016.3544","volume":"12","author":"J Hu","year":"2016","unstructured":"Hu J, Wang Y, Gong H, Yu C, Guo C, Wang F, et al. Long term effect and safety of Wharton\u2019s jelly-derived mesenchymal stem cells on type 2 diabetes. Exp Ther Med. 2016;12(3):1857\u201366.","journal-title":"Exp Ther Med"},{"issue":"9","key":"3054_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3727\/096368913X665576","volume":"23","author":"A Bhansali","year":"2014","unstructured":"Bhansali A, Asokumar P, Walia R, Bhansali S, Gupta V, Jain A, et al. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant. 2014;23(9):1075\u201385.","journal-title":"Cell Transplant"},{"key":"3054_CR24","doi-asserted-by":"crossref","unstructured":"Bhansali S, Dutta P, Kumar V, Yadav MK, Jain A, Mudaliar S, et al. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: a randomized, placebo-controlled comparative study. Stem Cells Dev. 2016;26(7):471\u201381.","DOI":"10.1089\/scd.2016.0275"},{"issue":"9","key":"3054_CR25","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.2337\/dc14-2830","volume":"38","author":"JS Skyler","year":"2015","unstructured":"Skyler JS, Fonseca VA, Segal KR, Rosenstock J. Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care. 2015;38(9):1742\u20139.","journal-title":"Diabetes Care"},{"issue":"8","key":"3054_CR26","first-page":"541","volume":"50","author":"M Ghodsi","year":"2012","unstructured":"Ghodsi M, Heshmat R, Amoli M, Keshtkar AA, Arjmand B, Aghayan H, et al. The Effect of Fetal Liver-Derived Cell Suspension Allotransplantation on Patients with Diabetes: First Year of Follow-up. Acta Med Iran. 2012;50(8):541\u20136.","journal-title":"Acta Med Iran"},{"key":"3054_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40200-014-0126-x","volume":"14","author":"E Nasli-Esfahani","year":"2015","unstructured":"Nasli-Esfahani E, Ghodsi M, Amini P, Keshtkar AA, Amiri S, Mojahed-Yazdi N, et al. Evaluation of fetal cell transplantation safety in treatment of diabetes: a three-year follow-up. J Diabetes Metab Disord. 2015;14:33.","journal-title":"J Diabetes Metab Disord"},{"issue":"9","key":"3054_CR28","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.2337\/diacare.28.9.2155","volume":"28","author":"P Huang","year":"2005","unstructured":"Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor\u2013 mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28(9):2155\u201360.","journal-title":"Diabetes Care"},{"key":"3054_CR29","doi-asserted-by":"publisher","unstructured":"Mirzaei M, Bagherinasabsarab M, Pakmanesh H, Mohammadi R, Teimourian M, Jahani Y, Farsinejad A. The Effect of Intracavernosal Injection of Stem Cell in the Treatment of Erectile Dysfunction in Diabetic Patients: A Randomized Single-blinded Clinical Trial. Urol J. 2021;18(6):675\u201381. https:\/\/doi.org\/10.22037\/uj.v18i.6503.","DOI":"10.22037\/uj.v18i.6503"},{"key":"3054_CR30","doi-asserted-by":"publisher","first-page":"5740923","DOI":"10.1155\/2020\/5740923","volume":"2020","author":"SY Sun","year":"2020","unstructured":"Sun SY, Gao Y, Liu GJ, Li YK, Gao W, Ran XW. Efficacy and safety of stem cell therapy for T1DM: an updated systematic review and meta-analysis. J Diabetes Res. 2020;2020:5740923.","journal-title":"J Diabetes Res"},{"issue":"1","key":"3054_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s13287-020-01996-x","volume":"11","author":"DH Kassem","year":"2020","unstructured":"Kassem DH, Kamal MM. Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study. Stem Cell Res Ther. 2020;11(1):484.","journal-title":"Stem Cell Res Ther"},{"key":"3054_CR32","doi-asserted-by":"publisher","first-page":"e0151938","DOI":"10.1371\/journal.pone.0151938","volume":"11","author":"A El-Badawy","year":"2016","unstructured":"El-Badawy A, El-Badri N. Clinical efficacy of stem cell therapy for diabetes mellitus: a meta-analysis. PLoS ONE. 2016;11:e0151938.","journal-title":"PLoS ONE"},{"issue":"1","key":"3054_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7150\/ijms.21666","volume":"15","author":"V Volarevic","year":"2018","unstructured":"Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, et al. Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 2018;15(1):36.","journal-title":"Int J Med Sci"},{"issue":"3","key":"3054_CR34","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1210\/er.2008-0031","volume":"30","author":"B Lo","year":"2009","unstructured":"Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev. 2009;30(3):204.","journal-title":"Endocr Rev"},{"issue":"Suppl 2","key":"3054_CR35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/sctm.21-0269","volume":"10","author":"T Lappin","year":"2021","unstructured":"Lappin T, Cheng T. An urgent need for standardization of stem cells and stem cell-derived products toward clinical applications. Stem Cells Transl Med. 2021;10(Suppl 2):S1\u20133.","journal-title":"Stem Cells Transl Med"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-03054-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-03054-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-03054-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:00:40Z","timestamp":1773057640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-025-03054-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3054"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-03054-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5569519\/v1","asserted-by":"object"}]},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}